Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalSTU:SD4 +1.23%14 OCF Yield % is -2.64 as of Jul. 15, 2026. GuruFocus rates STU:SD4 with a GF Score™ of 14/100 and a GF Value™ of €0.56 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 63.38% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Spectral Medical's OCF Yield % or its related term are showing as below:
STU:SD4'
s OCF Yield % Range Over the Past 10 Years
Min: -27.26 Med: -5.19 Max: 1.72
Current: -2.64
During the past 13 years, the highest OCF Yield % of Spectral Medical was 1.72%. The lowest was -27.26%. And the median was -5.19%.
STU:SD4's OCF Yield % is ranked worse than 63.38% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.04
vs STU:SD4: -2.64
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Spectral Medical OCF Yield % Related Terms
Spectral Medical OCF Yield % Historical Data
* Premium members only.
The historical data trend for Spectral Medical's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Spectral Medical's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Spectral Medical's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical (STU:SD4) has a OCF Yield % of -2.64 as of Jul. 15, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Spectral Medical and its competitors. According to the industry distribution chart, Spectral Medical ranks #135 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 63.4%.
Is Spectral Medical's OCF Yield % too high?
Spectral Medical's current OCF Yield % is -2.64. Based on the distribution chart, Spectral Medical ranks #135 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Spectral Medical has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #135 out of 213 companies for OCF Yield %. This places Spectral Medical in the lower half of its industry. The industry median OCF Yield % is 1.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.04, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Spectral Medical and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current OCF Yield % is -2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (STU:SD4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.56, compared to a current price of €0.83 — trading 47.3% above its estimated fair value. The current OCF Yield % is -2.64. Spectral Medical's overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Spectral Medical (STU:SD4), the current OCF Yield % is -2.64 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (STU:SD4) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of €0.83 is trading 47.3% above its estimated GF Value™ of €0.56.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for STU:SD4:
OCF Yield %: -2.64
GF Value™: €0.56 vs. price of €0.83 (47.3% above fair value)
No single metric tells the full story. See the STU:SD4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
14GF Score
Get the complete analysis for STU:SD4
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SD4 has been successfully added to your 
